Top Tech Companies (1,920)
Don't see your company?
Create a company profile
Pioneering generative biology to create breakthrough therapeutics.
For two hundred years vaccines have been administered by intramuscular injection. Vaxart’s oral vaccine pills may change everything. Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including the mouth, the nose and the gut. They are designed to trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders. Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Alluminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland. For more information, visit www.rakuten-med.com.
Putnam is a premier strategy consulting firm serving biopharmaceutical, diagnostics, medical device clients, and the private equity / venture capital community. For 30 years, we have offered objective, high impact strategic advice and analytical services, helping to support clients in crucial business decisions at all stages of the product and franchise lifecycle. Putnam is part of Inizio Advisory. Inizio is a strategic partner for health and life sciences with a full suite of medical, marketing, advisory and engagement services.
Precision is the first global precision medicine clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.
Culture’s mission is to make bioprocess development and scale-up as fast and easy as scaling software. Towards this aim, Culture’s first offering enables biopharma, biotechnology, and synthetic biology companies to run their bioprocessing R&D in the cloud. Clients design, manage, and analyze bioprocess experiments in Culture’s Console web application. Culture’s offering enables customers to focus on designing and improving their process versus spending time and effort building out their own high-throughput process development laboratory. While customers remotely observe the process and analyze data, the experiments are executed in Culture’s cloud bioreactor facility in South San Francisco. The facility is enabled by Culture’s proprietary 250mL and 5L single-use bioreactor technology and software systems. At Culture, we combine our passions for biomanufacturing, engineering, and operations to build new solutions that make bioprocess development and scale-up faster.
Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With offices in Santa Monica, CA and Amsterdam, the Netherlands, Neogene is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group
all.health has developed a comprehensive preventative and proactive healthcare platform that combines clinical-grade sensors, machine learning, patient histories, insurance claims data, and other information to provide real-time at-risk screening for several disease conditions; these include acute respiratory infections such as COVID-19, and chronic conditions such as hypertension and diabetes. Contextualized 24/7 data along with clinician input and interventions will then be used to guide positive behavior changes. The premise is to catch various health conditions early and help reverse or manage the negative effects.
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/
INOVIO Pharmaceuticals, Inc. (INOVIO) is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and protect people from infectious diseases, cancer and HPV-associated diseases. INOVIO’s DNA medicines platform and proprietary smart device can target virtually any DNA sequence. With 15 clinical programs currently in development, INOVIO has the potential to save and protect lives worldwide and power a new decade of DNA medicines. For more information, visit www.inovio.com.
Leading the field in the discovery of drugs that modulate the effects of cortisol. The adverse effects of excess cortisol have been Corcept’s focus since the company’s inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol.
Zack Abbott, PhD microbiologist, founded ZBiotics because of the potential genetically engineered probiotics have to improve daily living. Our first product is a probiotic that helps you feel better the day after drinking alcohol. ZBiotics is leveraging its patented technology to create a whole new category of products that help our bodies deal with whatever modern life throws our way. It’s genetic engineering as it should be: transparent, responsible, and people first.
Octant is a well-backed team of experienced technologists and entrepreneurs navigating the complexity of biology and chemistry to develop next generation small molecules. Combining advanced cell engineering, high-throughput chemistry, and automation we are engineering best-in-class drugs across rare disease, oncology, and immunology.
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions worldwide have used GenScript’s premier, convenient, and reliable products and services. GenScript currently has over 5,000 employees globally, 33% holding master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 100 patents and over 270 patent applications. As of June 2022, GenScript's products and services have been cited by 74,700 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
Gator Bio is a Silicon Valley biotech company with a mission to help biopharma scientists gain research insights faster. We fused engineering and science expertise to create novel analytical technologies that achieve better performance and more convenient solutions at a fraction of the cost of existing products. This is the biolayer interferometry solution you've been waiting for.
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data
AbSci is a leading synthetic biology company that translates ideas into drugs with a platform technology that reinvents the biopharmaceutical drug discovery process.
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
As a global healthcare company, we understand customer needs and innovate and deliver medical solutions that transform patient care. Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 300 individuals. Merit employs approximately 6,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.
